These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22149573)

  • 21. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
    Lin CH; Kohli R
    Curr Gastroenterol Rep; 2020 Aug; 22(10):52. PubMed ID: 32814993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
    Lomonaco R; Sunny NE; Bril F; Cusi K
    Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of vitamin supplementation to alter the fatty liver syndrome caused by aflatoxin.
    Hamilton PB; Garlich JD
    Poult Sci; 1972 Mar; 51(2):688-92. PubMed ID: 4629962
    [No Abstract]   [Full Text] [Related]  

  • 25. Adiponectin levels in nonalcoholic fatty liver disease.
    Abenavoli L
    Metabolism; 2011 Dec; 60(12):e3. PubMed ID: 21917277
    [No Abstract]   [Full Text] [Related]  

  • 26. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
    Westfall E; Jeske R; Bader AR
    Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
    Sanyal AJ; Chalasani N; Kowdley KV; McCullough A; Diehl AM; Bass NM; Neuschwander-Tetri BA; Lavine JE; Tonascia J; Unalp A; Van Natta M; Clark J; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
    N Engl J Med; 2010 May; 362(18):1675-85. PubMed ID: 20427778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fatty liver and raised gamma-GT: it can happen to abstainers, too].
    Bischoff A
    MMW Fortschr Med; 2002 Feb; 144(7):18. PubMed ID: 11887726
    [No Abstract]   [Full Text] [Related]  

  • 29. [Non-alcoholic liver disease - diagnosis and treatment].
    Sarosiekjeznach-Steinhagen A; Ostrowska J; Czerwonogrodzka-Senczyna A; Boniecka I
    Pol Merkur Lekarski; 2017 Nov; 43(257):237-242. PubMed ID: 29231919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):602-3; author reply 603-4. PubMed ID: 19183340
    [No Abstract]   [Full Text] [Related]  

  • 32. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
    Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K
    Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat.
    Raso GM; Esposito E; Iacono A; Pacilio M; Cuzzocrea S; Canani RB; Calignano A; Meli R
    Eur J Pharmacol; 2009 Feb; 604(1-3):125-31. PubMed ID: 19135440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
    Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
    World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?
    Beaton MD; Al-Judaibi B
    Saudi J Gastroenterol; 2016; 22(3):169-70. PubMed ID: 27184632
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence.
    Diakou MC; Liberopoulos EN; Mikhailidis DP; Tsianos EV; Burroughs AK; Elisaf MS
    Scand J Gastroenterol; 2007 Feb; 42(2):139-47. PubMed ID: 17327932
    [No Abstract]   [Full Text] [Related]  

  • 37. Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis.
    Hirsova P; Gores GJ
    Hepatology; 2015 Jan; 61(1):15-7. PubMed ID: 24975580
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Nadeau KJ; Ehlers LB; Zeitler PS; Love-Osborne K
    Pediatr Diabetes; 2009 Feb; 10(1):5-13. PubMed ID: 18721166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.
    Vos MB; Colvin R; Belt P; Molleston JP; Murray KF; Rosenthal P; Schwimmer JB; Tonascia J; Unalp A; Lavine JE;
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):90-6. PubMed ID: 22197855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.